AstraZeneca in the Vaccine Race; Ballots in Georgia
Squawk Pod - see all episodes
AstraZeneca’s Covid vaccine is the third one to prove highly effective in late-stage trials. AstraZeneca Executive Vice President Ruud Dobber explains differentiators of his company’s vaccine, and why between his company, Pfizer, and Moderna, he has high hopes for an accessible vaccine. New York Times columnist Thomas Friedman discusses the next steps in the race for a vaccine and in the Presidential transition. Plus, political pollster and strategist Frank Luntz unpacks what’s at stake on the ballots in Georgia. Learn more about your ad choices. Visit megaphone.fm/adchoices
Transcript
You can find here full transcripts for this episode of Squawk Pod. We're working hard to bring transcripts of all episodes to the web. Please download our mobile app to see transcripts for this episode.
Subscribe to new episodes
Subscribe to get an email every time this podcast publishes a new episode
Thanks for your interest!